WilmerHale Represents Pandion Therapeutics in $58M Series A Financing

Download IconDownload Print IconPrint

WilmerHale Represents Pandion Therapeutics in $58M Series A Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On January 18, 2018, Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, announced its $58 million Series A financing. Pandion intends to use the proceeds to advance tissue-specific immune modulator drugs for autoimmune and inflammatory diseases. The round was led by Polaris Partners, Versant Ventures, and Roche Venture Fund, with participation from SR One and BioInnovation Capital.  

The WilmerHale team representing Pandion included Lia Der Marderosian, Stephanie Singer, Andrea Sorrentino and Howell Ma.

Read Pandion's press release. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel